Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

AIM: To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. MATERIALS AND METHODS: STEP 1 (NCT03548935) randomized 1961 adults with a body mass index ≥ 30 kg/m(2) (or ≥ 27 kg/m(2) with ≥ 1 weight‐related co‐morbidity) without diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilding, John P. H., Batterham, Rachel L., Davies, Melanie, Van Gaal, Luc F., Kandler, Kristian, Konakli, Katerina, Lingvay, Ildiko, McGowan, Barbara M., Oral, Tugce Kalayci, Rosenstock, Julio, Wadden, Thomas A., Wharton, Sean, Yokote, Koutaro, Kushner, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/
https://www.ncbi.nlm.nih.gov/pubmed/35441470
http://dx.doi.org/10.1111/dom.14725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/
https://www.ncbi.nlm.nih.gov/pubmed/35441470
http://dx.doi.org/10.1111/dom.14725

Ejemplares similares